Unique ID issued by UMIN | UMIN000019502 |
---|---|
Receipt number | R000022540 |
Scientific Title | The clinical study to evaluate the utility of LC-1000 (exfoliative cell analyzer) for cervical cancer testing |
Date of disclosure of the study information | 2015/11/18 |
Last modified on | 2020/05/04 09:45:31 |
The clinical study to evaluate the utility of LC-1000 (exfoliative cell analyzer) for cervical cancer testing
The clinical study to evaluate the utility of LC-1000 (exfoliative cell analyzer) for cervical cancer testing
The clinical study to evaluate the utility of LC-1000 (exfoliative cell analyzer) for cervical cancer testing
The clinical study to evaluate the utility of LC-1000 (exfoliative cell analyzer) for cervical cancer testing
Japan |
Cervical cancer
Obstetrics and Gynecology |
Malignancy
NO
The aim of this study is to evaluate the clinical utility of new test by LC1000(exfoliative cell analyzer) for cervical cancer testing by comparison with HPV testing in the approximately 1 year follow-up.
Others
To compare the standard cervical cytology with the result of LC-1000analyzer.
Not applicable
Difference of the Accuracy (Sensitivity for the "Disease case" defined as CIN2 or worse) and Specificity for the "Non-Disease case" defined as the case that dysplasia is not confirmed in this study period ) between the new test by LC-1000 analyzer and HPV test.
Accuracy (Sensitivity and Specificity) between LC-1000 test and cytology for the detection of CIN2 or worse.
Accuracy (Sensitivity and Specificity) between LC-1000 test and other test (combination or alone test by cytology, HPV test) for the detection of CIN3 or worse.
Observational
20 | years-old | <= |
70 | years-old | > |
Female
(1)Women whom close examination is required
Women who diagnosed ASC-US or worse within 24 weeks, or suspected cervical abnormalities in past clinical findings
Women who can cooperate the specimen collection
Women who provided informed consent
(2)Women for the pap smear (1st screening test)
Women who provided informed
Women who have had cervical invasive cancer before.
Women who have underwent cervical conization or hysterectomy before.
Pregnant women
Women judged ineligible for this study by investigator.
930
1st name | |
Middle name | |
Last name | Daisuke Aoki |
Keio University, School of Medicine
Department of Obstetrics and Gynecology
35 Shinanomachi, Shinjyuku-ku, Tokyo,160-8582, Japan
03-3353-1211
aoki@z7.keio.jp
1st name | |
Middle name | |
Last name | Masaru Nakamura |
Keio University, School of Medicine
Department of Obstetrics and Gynecology
35 Shinanomachi, Shinjyuku-ku, Tokyo,160-8582, Japan
03-3353-1211
naka44725@a2.keio.jp
The Japanese Society of Clinical Cytology
Sysmex corporation
Profit organization
Department of Diagnostic Pathology, Kumamoto University Hospital
NO
慶應義塾大学医学部附属病院(東京都)
公益財団法人 大阪がん循環器病予防センター(大阪府)
公益財団法人 東京都予防医学協会(東京都)
2015 | Year | 11 | Month | 18 | Day |
Unpublished
Completed
2015 | Year | 06 | Month | 30 | Day |
2015 | Year | 09 | Month | 25 | Day |
2015 | Year | 10 | Month | 15 | Day |
2017 | Year | 09 | Month | 30 | Day |
2017 | Year | 09 | Month | 30 | Day |
Case control study
Women who come to our hospital and meet the key inclusion criteria
To measureCPIx as a cellular proliferative potential by LC-1000 analyzer.
2015 | Year | 10 | Month | 26 | Day |
2020 | Year | 05 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022540
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |